A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 228 participants.

Also called NCT07021976

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 228 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07021976
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07021976. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-11 (actual); primary completion 2026-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
Condition
Obstructive Hypertrophic Cardiomyopathy
Intervention (Drug)
HRS-1893 Tablets
Intervention (Drug)
HRS-1893 Placebo Tablets
Lead sponsor
Shandong Suncadia Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07021976
Content hash
432416e0e32ee1e2ab90dfc04e09de0c3e28024f31fa8de10dba609108b6c7c2